GLP-1-based therapies: the dilemma of uncertainty

Gastroenterology. 2011 Jul;141(1):20-3. doi: 10.1053/j.gastro.2011.05.019.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dipeptidyl-Peptidase IV Inhibitors / adverse effects*
  • Exenatide
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Pancreatic Neoplasms / chemically induced*
  • Pancreatitis / chemically induced*
  • Peptides / adverse effects
  • Pyrazines / adverse effects
  • Receptors, Glucagon / agonists*
  • Risk Assessment
  • Risk Factors
  • Sitagliptin Phosphate
  • Thyroid Neoplasms / chemically induced*
  • Triazoles / adverse effects
  • Uncertainty
  • Venoms / adverse effects

Substances

  • Dipeptidyl-Peptidase IV Inhibitors
  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Peptides
  • Pyrazines
  • Receptors, Glucagon
  • Triazoles
  • Venoms
  • Exenatide
  • Sitagliptin Phosphate